Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Acta Diabetologica
Published in: Acta Diabetologica 4/2011

01-12-2011 | Letter to the Editor

Higher liver transaminase levels and oral hypoglycemic drug therapy failure in patients with type 2 diabetes: is iron the missing link?

Authors: Luca Mascitelli, Mark R. Goldstein

Published in: Acta Diabetologica | Issue 4/2011

Login to get access

Excerpt

Dear Sir, …
Literature
1.
Irace C, Rossetti M, Carallo C, Morano S, Vespertini V, Mandosi E, Maranghi M, Fiorentino R, Filetti S, Gnasso A (2011) Transaminase levels in the upper normal range are associated with oral hypoglycemic drug therapy failure in patients with type 2 diabetes. Acta Diabetol. doi:10.​1007/​s00592-011-0261-s
2.
Rajpathak SN, Crandall JP, Wylie-Rosett J, Kabat GC, Rohan TE, Hu FB (2009) The role of iron in type 2 diabetes in humans. Biochim Biophys Acta 1790:671–681PubMedCrossRef
3.
Mascitelli L, Pezzetta F, Goldstein MR (2009) Hyperinsulinaemia and iron perturbation in patients with type 2 diabetes. Int J Clin Pract 63:672PubMedCrossRef
4.
Tuomainen TP, Nyyssönen K, Salonen R, Tervahauta A, Korpela H, Lakka T, Kaplan GA, Salonen JT (1997) Body iron stores are associated with serum insulin and blood glucose concentration: population study in 1, 013 eastern Finnish men. Diabetes Care 20:426–428PubMedCrossRef
5.
Ford ES, Cogswell ME (1999) Diabetes and serum ferritin concentration among U.S. adults. Diabetes Care 22:1978–1983PubMedCrossRef
6.
Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB (2004) Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 291:711–717PubMedCrossRef
7.
Facchini FS, Saylor KL (2002) Effect of iron depletion on cardiovascular risk factors: studies in carbohydrate intolerant patients. Ann NY Acad Sci 967:342–351PubMedCrossRef
8.
Fernandez-Real JM, Penarroja G, Castro A, Garcia-Bragado F, Hernandez-Aguado I, Ricart W (2002) Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes 51:1000–1004PubMedCrossRef
9.
George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, Jazwinska EC, Powell LW (1998) Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 114:311–318PubMedCrossRef
10.
Sumida Y, Nakashima T, Yoh T, Furutani M, Hirohama A, Kakisaka Y, Nakajima Y, Ishikawa H, Mitsuyoshi H, Okanoue T, Kashima K, Nakamura H, Yodoi J (2003) Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. J Hepatol 38:32–38PubMedCrossRef
11.
Valenti L, Fracanzani AL, Dongiovanni P, Bugianesi E, Marchesini G, Manzini P, Vanni E, Fargion S (2007) Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 102:1251–1258PubMedCrossRef
12.
Sumida Y, Kanemasa K, Fukumoto K, Yoshida N, Sakai K, Nakashima T, Okanoue T (2006) Effect of iron reduction by phlebotomy in Japanese patients with nonalcoholic steatohepatitis: a pilot study. Hepatol Res 36:315–321PubMedCrossRef
13.
Okuda M, Sasaki S, Kunitsugu I, Sakurai R, Yoshitake N, Hobara T (2011) Iron load and liver enzymes in 10- and 13-year-olds. J Pediatr Gastroenterol Nutr 52:333–338PubMedCrossRef
Metadata
Title
Higher liver transaminase levels and oral hypoglycemic drug therapy failure in patients with type 2 diabetes: is iron the missing link?
Authors
Luca Mascitelli
Mark R. Goldstein
Publication date
01-12-2011
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 4/2011
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-011-0282-0

Other articles of this Issue 4/2011

Acta Diabetologica 4/2011 Go to the issue

Original Article

The ENPP1 K121Q polymorphism is not associated with type 2 diabetes in northern Chinese

Original Article

The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus

Original Article

HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas

Case Report

Iatrogenic diabetes mellitus during ACTH therapy in an infant with West syndrome

Review Article

Gut microbiota and diabetes: from pathogenesis to therapeutic perspective

Original Article

Leptin is an independent determinant of bone mineral density in men with type 2 diabetes mellitus
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits